An Efficacy and Safety Study of ABT-SLV176 for the Treatment of Hypogonadal Men
NCT ID: NCT02082197
Last Updated: 2014-06-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE3
INTERVENTIONAL
2014-03-31
2015-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of the Safety, Tolerability and Pharmacokinetics of Testosterone Undecanoate in Hypogonadal Males.
NCT01346319
Safety and Efficacy Trial of Testosterone Undecanoate
NCT01765179
A Study in Men With Low Testosterone to Measure the Effects of Testosterone Solution on Testosterone Levels, Sex Drive and Energy
NCT01816295
Does Testosterone Improve Function in Hypogonadal Older Men
NCT00304213
The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel
NCT01893281
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ABT-SLV176
ABT-SLV176 administered daily
ABT-SLV176
ABT-SLV176 administered daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ABT-SLV176
ABT-SLV176 administered daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Elevated Prostatic Specific Antigen (PSA)
* History of breast or prostate cancer
18 Years
80 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AbbVie
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael Miller, PharmD
Role: STUDY_DIRECTOR
AbbVie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Site Reference ID/Investigator# 124163
Birmingham, Alabama, United States
Site Reference ID/Investigator# 123938
Huntsville, Alabama, United States
Site Reference ID/Investigator# 125782
Mesa, Arizona, United States
Site Reference ID/Investigator# 124157
Phoenix, Arizona, United States
Site Reference ID/Investigator# 123937
Tucson, Arizona, United States
Site Reference ID/Investigator# 123948
Anaheim, California, United States
Site Reference ID/Investigator# 124164
Los Angeles, California, United States
Site Reference ID/Investigator# 123920
Los Gatos, California, United States
Site Reference ID/Investigator# 124038
Colorado Springs, Colorado, United States
Site Reference ID/Investigator# 126202
Denver, Colorado, United States
Site Reference ID/Investigator# 123927
Middlebury, Connecticut, United States
Site Reference ID/Investigator# 123947
Clearwater, Florida, United States
Site Reference ID/Investigator# 123929
Jacksonville, Florida, United States
Site Reference ID/Investigator# 123940
Ocala, Florida, United States
Site Reference ID/Investigator# 124166
Orlando, Florida, United States
Site Reference ID/Investigator# 123945
Ponte Vedra Beach, Florida, United States
Site Reference ID/Investigator# 123930
Dunwoody, Georgia, United States
Site Reference ID/Investigator# 124395
Wichita, Kansas, United States
Site Reference ID/Investigator# 125784
Crestview Hills, Kentucky, United States
Site Reference ID/Investigator# 123919
Lexington, Kentucky, United States
Site Reference ID/Investigator# 123925
Baltimore, Maryland, United States
Site Reference ID/Investigator# 123936
Methuen, Massachusetts, United States
Site Reference ID/Investigator# 124160
Las Vegas, Nevada, United States
Site Reference ID/Investigator# 123939
Las Vegas, Nevada, United States
Site Reference ID/Investigator# 123932
Lawrenceville, New Jersey, United States
Site Reference ID/Investigator# 123943
Albuquerque, New Mexico, United States
Site Reference ID/Investigator# 123926
Garden City, New York, United States
Site Reference ID/Investigator# 125783
New York, New York, United States
Site Reference ID/Investigator# 123928
Poughkeepsie, New York, United States
Site Reference ID/Investigator# 124165
Charlotte, North Carolina, United States
Site Reference ID/Investigator# 123933
Morehead City, North Carolina, United States
Site Reference ID/Investigator# 123921
Salisbury, North Carolina, United States
Site Reference ID/Investigator# 124162
Cleveland, Ohio, United States
Site Reference ID/Investigator# 123917
Bala-Cynwyd, Pennsylvania, United States
Site Reference ID/Investigator# 123931
Jenkintown, Pennsylvania, United States
Site Reference ID/Investigator# 123924
Greer, South Carolina, United States
Site Reference ID/Investigator# 123895
Chattanooga, Tennessee, United States
Site Reference ID/Investigator# 123946
Nashville, Tennessee, United States
Site Reference ID/Investigator# 123923
Austin, Texas, United States
Site Reference ID/Investigator# 123922
Dallas, Texas, United States
Site Reference ID/Investigator# 124167
Dallas, Texas, United States
Site Reference ID/Investigator# 123944
San Antonio, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
M13-886
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.